新冠疫情期间泌尿肿瘤手术等待时间安全性的系统综述
结论认为多数前列腺癌治疗可推迟至180天,但诊断性膀胱镜、经尿道膀胱肿瘤电切及cT2+肾肿块肾切除术应30天内完成,cT1肾肿块、肌层浸润性膀胱癌、上尿路尿路上皮癌及高危前列腺癌应在90天内开始治疗。
要点
- 诊断性膀胱镜、经尿道膀胱肿瘤电切及cT2+肾肿块肾切除术应30天内完成
- cT1肾肿块、肌层浸润性膀胱癌、上尿路尿路上皮癌及高危前列腺癌应在90天内开始治疗
- 多数前列腺癌治疗可安全推迟至180天
核心结论
- 关于新冠相关治疗延迟影响的研究较少,是错失的机会
- 多数前列腺癌治疗可推迟至180天
- 诊断性膀胱镜、经尿道膀胱肿瘤电切及cT2+肾肿块肾切除术应30天内完成
- cT1肾肿块、肌层浸润性膀胱癌、上尿路尿路上皮癌及高危前列腺癌应在90天内开始治疗
研究设计与样本
- 纳入报告治疗延迟对手术或肿瘤结局或患者体验影响的研究
- 优先纳入疫情开始后建立队列的研究,共35项研究符合纳入标准
主要发现
- 6项尿路上皮癌研究报告延迟2周至3个月与阴性临床结局相关,3项报告中性影响
- 4项肾癌研究报告延迟1-3个月与阴性结局相关,2项报告中性影响
- 1项阴茎癌研究报告治疗延迟与更差生存相关,未检索到睾丸癌研究
- 5项研究报告延迟对患者体验有负面影响,1项报告正面体验
关键数值与推荐
- 尿路上皮癌延迟2周至3个月:6项研究报告阴性结局,3项中性
- 肾癌延迟1-3个月:4项研究报告阴性结局,2项中性
- 阴茎癌治疗延迟:1项研究报告更差生存
临床怎么用
- 诊断性膀胱镜、经尿道膀胱肿瘤电切及cT2+肾肿块肾切除术应在30天内完成
- cT1肾肿块、肌层浸润性膀胱癌、上尿路尿路上皮癌及高危前列腺癌应在90天内开始治疗
- 多数前列腺癌治疗可推迟至180天
局限性
- 仅35项研究符合纳入标准,关于新冠相关延迟影响的研究较少
- 21项研究仅纳入疫情前队列,其建议基于间接推断
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To review papers assessing the impact of surgical delay in relation to the COVID-19 pandemic, and evaluate what has been learnt about the safety of surgical waiting times in urological oncology. PATIENTS AND METHODS: Medline and Web of Science were searched for studies published between 1 January 2020 and 1 November 2024. Studies included were those reporting treatment delay effects on surgical or oncological outcomes, or patient experience with reference to COVID-19. Priority was given to studies deriving their cohort after the start of the pandemic. Studies were also included in which the cohort was derived before the pandemic, but where recommendations were made on COVID-19 treatment delay. Data were extracted regarding duration of delay and authors' reported impact of delay on outcome (quantified, and simplified as negative/neutral/positive). RESULTS: A total of 35 studies met the inclusion criteria. Fourteen studies included data collected after the start of the pandemic and 21 exclusively included cohorts derived prior to the pandemic but made recommendations about COVID-19-related treatment delays. Six studies on urothelial cancer reported negative clinical outcomes for delays between 2 weeks and 3 months, while three reported a neutral impact. Four studies on kidney cancer reported negative outcomes with 1-3-month delay, while two reported a neutral impact. Eleven studies on prostate cancer reported that a 3-12-month delay had neutral effects, while one reported negative outcomes. One study on penile cancer reported worse survival with delays in treatment. No studies on testicular cancer were identified. Five studies reported negative patient experience with delays, while one reported a positive patient experience. CONCLUSIONS: Few studies have reported the impacts of COVID-19-related delayed treatment; this was a missed opportunity. While most prostate cancer treatment can be deferred up to 180 days, diagnostic cystoscopy, transurethral resection of bladder tumour and nephrectomy for cT2+ renal masses should be expedited to occur within 30 days. Treatment of cT1 renal masses, carcinoma invading bladder muscle, upper tract urothelial carcinoma and high-risk prostate cancer should commence within 90 days.
引用
- Blackmur JP, Re C, Stewart GD, et al. What has the COVID-19 pandemic taught us about safety of surgical wait times in urological oncology? BJU Int. 2025. PMID: 40764711. doi:10.1111/bju.16881
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。